Lucitanib11 has been evaluated in patients with ER positive breast cancer; here, the response rate was 25% in FGFR-high breast cancers (by immunohistochemistry) compared with 8% in low-FGFR1 tumours, but the numbers of patients were small and, although suggestive of a relationship, this result was not conclusive. This evidence concerns the gene FGFR1 and breast carcinoma.